BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Former Stryker CEO Takes Reins at sBioMed


11/2/2012 9:00:30 AM

OREM, Utah, Nov. 1, 2012 /PRNewswire/ -- sBioMed, an emerging leader in infection control, announced today that Stephen P. MacMillan, former Chairman and CEO of Stryker, has joined the company as Chief Executive Officer and become an owner of the company.

sBioMed has developed breakthrough patented antimicrobial technologies, offering an unprecedented level of efficacy and safety. The company's flagship product STERIPLEX SD is the first and only Clostridium difficile sporicide and broad-spectrum, one-step disinfectant, which is also remarkably safe, completely non-fuming, non-corrosive, and contains no bleach.

The technology is similar to the company's anthrax remediation product, STERIPLEX Ultra, the only EPA-registered product available that kills anthrax spores.

Brian Larson, sBioMed's cofounder and chairman, said, "After a decade of research, over 500 studies and EPA-registration, we are excited to enter the full-scale commercialization process. With Steve's leadership, we can help eliminate Healthcare-Associated Infections (HAIs) globally."

"It's rare to find a product with such revolutionary potential," MacMillan said. "STERIPLEX SD will save lives, improve healthcare delivery and protect caregivers, while reducing healthcare costs and preserving the environment. I'm also excited about the chance to work with the sBioMed team to build a very special global company based in Utah."

With the growing incidence of C. diff and other superbugs, infections are now the fourth leading killer in the U.S., at a cost to the U.S. healthcare system of tens of billions of dollars annually. Effective January 1, 2013, costs associated with HAIs will no longer be reimbursed, giving hospitals a strong incentive to eliminate HAIs. Hospitals currently employing STERIPLEX SD have charted a significant drop in HAIs.

STERIPLEX SD is EPA-registered for use on food contact surfaces (NSF D2) and can even be used on children's toys. With the best MSDS health rating of "0," STERIPLEX SD provides broad-spectrum sporicidal disinfection for institutions that want to reduce HAIs, increase workplace safety, and eliminate their use of volatile organic compounds (VOCs).

Learn more about STERIPLEX on the company's website, www.steriplex.com.

SOURCE sBioMed



Read at BioSpace.com

Stryker
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES